Phase II Anti-NYESO-1 immunotherapy trial at NIH


For those who are looking for a trial right now, you should check whether you may be eligible for the following:


In the initial trial, 4 out of 6 synovial sarcoma patients responded:


In this trial, the method used to produce the anti-NYESO-1 is slightly different and may lead to even better results.

As with previous trial, patients must be HLA-A*0201 positive :-(


Thank you for posting this, Elodie. Good information.